Trispecific TCE (Antengene Corp Ltd)

N/A

Report date: 2026/03/19 20:00:18

First In Class

Base Information

Drug NameTrispecific TCE (Antengene Corp Ltd)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionUpdating

TargetsUpdating

Therapy Area/IndicationsProstatic Neoplasms, Castration-ResistantCarcinoma, Non-Small-Cell LungNeuroendocrine Tumors

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesAntengene Corp Ltd

China Registration ClassN/A

Develop Information

Active CompaniesAntengene Corp Ltd

Inactive CompaniesN/A

Active IndicationsProstatic Neoplasms, Castration-ResistantCarcinoma, Non-Small-Cell LungNeuroendocrine Tumors

Inactive IndicationsN/A

Other Information

ATC CodeN/A